Wos İndeksli Yayınlar Koleksiyonu

Permanent URI for this collectionhttps://hdl.handle.net/11727/4807

Browse

Filters

2017 - 20182

Settings

search.filters.applied.f.rights: search.filters.rights.info:eu-repo/semantics/openAccessSubject: search.filters.subject.Hyperglycemia

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Neonatal Hyperglycemia, which threshold value, diagnostic approach and treatment?: Turkish Neonatal and Pediatric Endocrinology and Diabetes Societies consensus report
    (2018) Gökşen Şimşek, D.; Ecevit, A.; Hatipoğlu, N.; Çoban, A.; Arısoy, A.E.; Baş, F.; Mutlu, G.Y.; Bideci, A.; Özek, E.; 0000-0002-2232-8117; 31236036; AAJ-4616-2021
    Hyperglycemia has become an important risk factor for mortality and morbidity in the neonatal period, especially with increased survival rates of very low birth weight babies. Hyperglycemia in the neonatal period develops as a result of various mechanisms including iatrogenic causes, inability to supress hepatic glucose production, insulin resistance or glucose intolerance, specifically in preterm babies. Initiation of parenteral or enteral feeding in the early period in preterm babies increases insulin production and sensitivity. The plasma glucose is targeted to be kept between 70 and 150 mg/dL in the newborn baby. While a blood glucose value above 150 mg/dL is defined as hyperglycemia, blood glucose values measured with an interval of 4 hours of >180-200 mg/dL and +2 glucosuria require treatment. Although glucose infusion rate is reduced in treatment, use of insulin is recommended, if two blood glucose values measured with an interval of 4 hours are >250 mg/dL and glucosuria is present in two separate urine samples. © 2018 by Turkish Pediatric Association.
  • Thumbnail Image
    Item
    Hyperglycemia in Hospital: Diagnosis, Classification, Clinical Implications and Treatment
    (2017) Bagir, Gulay Simsek; Ertorer, Melek Eda; 0000-0001-7357-8709; ABI-3705-2020
    Hyperglycemia is a well-recognized risk factor for hospital-related complications, prolonged stay in the hospital and even mortality. The patients with in-hospital hyperglycemia may be categorized into three groups: i) Patients who have been diagnosed as having diabetes mellitus (DM) before admission; ii) Patients with newly diagnosed DM; and iii) Patients with stress hyperglycemia. The release of stress hormones, such as cortisol, catecholamines, glucagon, growth hormone and the related acceleration in gluconeogenesis and glycogenolysis, medications used for the treatment of primary diseases, such as glucocorticoids and vasopressors, are all claimed to be responsible for the development of in-hospital hyperglycemia. Glucose normalization with insulin therapy has been demonstrated to significantly decrease the morbidity and mortality in all the three groups. Therefore, it is recommended to monitor blood glucose levels for all hospitalized patients irrespective of the accompanying DM diagnosis.